Your browser is no longer supported. Please, upgrade your browser.
UROV Urovant Sciences Ltd. daily Stock Chart
Urovant Sciences Ltd.
Index- P/E- EPS (ttm)-4.87 Insider Own2.20% Shs Outstand30.71M Perf Week5.78%
Market Cap295.33M Forward P/E- EPS next Y-4.52 Insider Trans0.00% Shs Float4.17M Perf Month4.24%
Income-148.80M PEG- EPS next Q-1.50 Inst Own21.10% Short Float20.47% Perf Quarter-11.05%
Sales- P/S- EPS this Y-9.00% Inst Trans-12.12% Short Ratio10.63 Perf Half Y3.66%
Book/sh-2.77 P/B- EPS next Y22.90% ROA-160.40% Target Price- Perf Year2.19%
Cash/sh1.99 P/C4.69 EPS next 5Y- ROE481.30% 52W Range6.55 - 15.98 Perf YTD-39.78%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.55% Beta-
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low42.60% ATR0.58
Employees70 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)55.01 Volatility6.04% 6.74%
OptionableNo Debt/Eq- EPS Q/Q-5.70% Profit Margin- Rel Volume0.89 Prev Close9.19
ShortableYes LT Debt/Eq- EarningsAug 13 AMC Payout- Avg Volume80.26K Price9.34
Recom1.70 SMA201.40% SMA507.36% SMA200-9.86% Volume71,151 Change1.63%
Mar-15-19Initiated SunTrust Buy $24
Mar-11-19Initiated H.C. Wainwright Buy $28
Oct-22-18Initiated JP Morgan Overweight $21
Oct-22-18Initiated Jefferies Buy $19
Sep-28-20 12:20PM  
Sep-08-20 08:00AM  
Aug-13-20 08:31PM  
Aug-06-20 08:00AM  
Jun-18-20 04:05PM  
Jun-14-20 08:22PM  
Jun-11-20 08:00AM  
Jun-02-20 08:00AM  
May-27-20 08:00AM  
May-26-20 08:00AM  
May-14-20 08:00AM  
Mar-23-20 04:05PM  
Mar-05-20 08:00AM  
Mar-02-20 08:00AM  
Feb-25-20 08:00AM  
Feb-13-20 04:15PM  
Feb-06-20 08:00AM  
Feb-04-20 08:00AM  
Jan-17-20 08:00AM  
Jan-08-20 08:00AM  
Jan-02-20 10:19AM  
Dec-31-19 08:57AM  
Dec-30-19 04:15PM  
Dec-23-19 08:00AM  
Dec-16-19 05:47AM  
Nov-05-19 04:05PM  
Oct-31-19 09:29AM  
Oct-29-19 08:00AM  
Oct-21-19 08:00AM  
Sep-24-19 09:00AM  
Sep-06-19 09:00AM  
Aug-13-19 08:23PM  
Aug-06-19 08:00AM  
Jun-29-19 06:08PM  
Jun-20-19 08:25AM  
Jun-13-19 04:05PM  
Jun-06-19 08:00AM  
Jun-03-19 08:00AM  
May-30-19 08:00AM  
May-06-19 08:00AM  
Apr-29-19 08:00AM  
Mar-27-19 08:00AM  
Mar-19-19 04:09PM  
Mar-18-19 04:05PM  
Mar-07-19 08:00AM  
Mar-06-19 08:00AM  
Feb-26-19 08:14PM  
Feb-22-19 05:20PM  
Feb-13-19 04:05PM  
Feb-06-19 08:00AM  
Jan-15-19 08:00AM  
Jan-03-19 08:00AM  
Jan-02-19 08:00AM  
Dec-19-18 08:00AM  
Nov-19-18 08:00AM  
Nov-12-18 04:05PM  
Nov-08-18 08:00AM  
Nov-05-18 08:00AM  
Nov-01-18 08:00AM  
Oct-11-18 06:41PM  
Sep-27-18 05:24PM  
Sep-26-18 11:00PM  
Sep-22-18 04:15PM  
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Bryan E.GC/Urovant Sciences, Inc.Feb 19Option Exercise6.8850,000344,000100,000Feb 21 06:42 PM
Katkin KeithPEO;CEO/Urovant Sciences, Inc.Feb 19Option Exercise3.86180,000694,800379,680Feb 21 06:42 PM
Sumitomo Chemical Co., Ltd.Feb 19Buy13.08103,2501,350,51022,963,263Feb 21 05:54 PM
Katkin KeithPEO;CEO/Urovant Sciences, Inc.Dec 09Option Exercise3.86120,000463,200120,000Dec 11 05:01 PM
Katkin KeithPEO;CEO/Urovant Sciences, Inc.Dec 09Sale12.78120,0001,533,6000Dec 11 05:01 PM